Pfizer stock: Wells Fargo keeps USD 28.00 target for Pfizer stock

Published on 10/19/2026 at 16:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Pfizer reports results on November 3, 2026. Pfizer stock costs EUR 26.39 on October 19, 2026, up 0.34 percent versus the Xetra close.

Analyst target and trading date

Wells Fargo maintained a USD 28.00 target for Pfizer on October 16, 2026.
Pfizer reports third-quarter results on November 3, 2026.
Pfizer stock costs EUR 26.39 at Lang & Schwarz on October 19, 2026 at 4:00 p.m. CEST, plus 0.34 percent versus the Xetra close of October 16, 2026.
Pfizer's market capitalization is USD 168.7 billion and its trailing P/E is 39.15.

Pfizer Inc., US7170811035, Illustration mit AI erstellt.

On October 16, 2026, Wells Fargo maintained a Hold rating and a USD 28.00 target for Pfizer, with the target 5.37 percent below the USD 29.59 NYSE price, according to The Globe and Mail. Pfizer stock was trading at EUR 26.39 at Lang & Schwarz on October 19, 2026 at 4:00 p.m. CEST, up 0.34 percent versus the Xetra close of October 16, 2026 at EUR 26.30.

November 3 results set the next date

Pfizer is scheduled to report its third-quarter 2026 results before the US market opens on November 3, 2026. The date is listed by MetaCap, which also identifies Pfizer as listed on the NYSE under ticker PFE. That event gives investors the next fixed checkpoint for revenue, earnings and the company's full-year outlook.

Stock remains near its yearly high

Pfizer's NYSE close was USD 29.58 on October 16, 2026, while the 52-week range was USD 23.62 to USD 29.88. The closing price was 1.00 percent below the 52-week high, and the stock was up 18.80 percent year to date, according to MetaCap. The Lang & Schwarz bid was EUR 26.38 and the ask was EUR 26.41 at 4:00 p.m. CEST on October 19, 2026.

Valuation carries the income signal

Pfizer's market capitalization was USD 168.7 billion and its trailing P/E was 39.15 on October 19, 2026. MetaCap listed a 5.81 percent dividend yield and an annual dividend of USD 1.72 as of October 16, 2026. The Wells Fargo target is below the NYSE price, putting the analyst view and the upcoming results date at the center of the stock's near-term information set.

Comparison with peers

Pfizer Inc.: plus 0.34 percent, P/E 39.15, market capitalization USD 168.7 billion
AbbVie Inc. (NYSE, USD): minus 0.08 percent, P/E 80.48, market capitalization USD 504.4 billion
Bristol-Myers Squibb Company (NYSE, USD): minus 0.81 percent, P/E 13.05, market capitalization USD 121.1 billion

Price and investor reference

The euro quote stood above the October 16 Xetra close by 0.34 percent, while the US listing's latest reported close remained below its 52-week high. The next scheduled reporting date is November 3, 2026.

The further course of trading is shown by the continuously updated real-time quote of Pfizer stock.